留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

移植肾抗体介导的排斥反应的病理学

郭晖

郭晖. 移植肾抗体介导的排斥反应的病理学[J]. 器官移植, 2021, 12(3): 262-271. doi: 10.3969/j.issn.1674-7445.2021.03.003
引用本文: 郭晖. 移植肾抗体介导的排斥反应的病理学[J]. 器官移植, 2021, 12(3): 262-271. doi: 10.3969/j.issn.1674-7445.2021.03.003
Guo Hui. Pathology of antibody-mediated rejection in renal allograft[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 262-271. doi: 10.3969/j.issn.1674-7445.2021.03.003
Citation: Guo Hui. Pathology of antibody-mediated rejection in renal allograft[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 262-271. doi: 10.3969/j.issn.1674-7445.2021.03.003

移植肾抗体介导的排斥反应的病理学

doi: 10.3969/j.issn.1674-7445.2021.03.003
基金项目: 

中国医学科学院中央级公益性科研院所基本科研业务费专项资金资助 2019PT320014

详细信息
    通讯作者:

    郭晖,研究方向为移植病理学基础与临床应用研究,Email: zcguo@tjh.tjmu.edu.cn

  • 中图分类号: R617, R36

Pathology of antibody-mediated rejection in renal allograft

More Information
  • 摘要: 抗体介导的排斥反应(AMR)亦称体液性排斥反应,是由抗体、补体等多种体液免疫效应因子参与所致的排斥反应免疫损伤。AMR在超急性排斥反应、急性排斥反应以及慢性排斥反应中均发挥了重要的致病作用。本文对AMR的基本定义、Banff移植病理学诊断标准(Banff标准)中AMR病理学的研究历程及其主要成果以及移植肾AMR的主要病变特征进行综述,旨在为准确诊断、及时治疗AMR提供依据,以保障移植肾和受者的长期存活。

     

  • 图  1  移植肾aAMR的C4d免疫组化染色表现

    注:A图示移植肾组织C4d免疫荧光染色呈弥漫性肾小管周毛细血管内皮细胞阳性(×200);B图示移植肾组织C4d免疫酶组化染色呈阳性(箭头所示)(×400)。

    Figure  1.  C4d immunohistochemical staining findings of aAMR in renal allograft

    图  2  移植肾aAMR的肾小球炎病理学表现

    注:图示肾小球毛细血管袢腔内中性粒细胞等炎症细胞浸润。A图为Masson三色染色(×200);B图为HE染色(×400);C图中电镜下可见肾小球毛细血管袢腔内多个淋巴细胞淤积(箭头所示)(×6 000)。

    Figure  2.  Pathological findings of glomerulitis of aAMR in renal allograft

    图  3  移植肾aAMR的肾小管周毛细血管炎病理学表现

    注:A图示肾小管周毛细血管的管腔扩张,管腔内有多个炎症细胞淤积、浸润(箭头所示)(PAS,×200);B图示肾小管周毛细血管内淋巴细胞(红色箭头所示)和中性粒细胞(黑色箭头所示)淤积浸润(HE,×1 000);C图示肾小管周毛细血管内皮细胞(箭头所示)C4d免疫酶组化染色阳性,管腔内炎症细胞淤积、浸润(星号所示)(×200)。

    Figure  3.  Pathological findings of peritubular capillaritis of aAMR in renal allograft

    图  4  移植肾aAMR的动脉内膜炎病理学表现

    注:A图示动脉内皮上少量淋巴细胞浸润,局部内膜轻度水肿(箭头所示)(HE,×200);B图示动脉内膜炎,动脉内膜明显水肿、增厚导致管腔狭窄,水肿增厚的内膜内可见淋巴细胞浸润(箭头所示)(HE,×400);C图示移植肾内动脉管壁纤维素样坏死(箭头所示)(HE,×400)。

    Figure  4.  Pathological findings of endarteritis of aAMR in renal allograft

    图  5  移植肾aAMR的TMA病理学表现

    注:图示肾小球毛细血管内皮细胞肿胀伴炎症细胞浸润,毛细血管内皮细胞下间隙增宽,部分毛细血管腔内微血栓栓塞(磷钨酸苏木素,×1 000)。

    Figure  5.  Pathological findings of TMA of aAMR in renal allograft

    图  6  移植肾caAMR的慢性TG病理学表现

    注:A图示弥漫性肾小球基底膜增厚及局灶性双轨征形成(箭头所示),肾小球内无嗜复红蛋白沉积(PASM,×200);B图示肾小球毛细血管基底膜增厚(星号所示)和双轨征形成(箭头所示)(Masson,×1 000);C图电镜下可见增生的系膜基质插入基底膜致毛细血管基底膜增厚呈双轨征(箭头所示)(×5 000)。

    Figure  6.  Pathological findings of chronic TG of caAMR in renal allograft

    图  7  移植肾caAMR的PTCML病理学表现

    注:图示电镜下可见肾小管周毛细血管基膜增生为6~7层(箭头所示)(×6 000)。

    Figure  7.  Pathological findings of PTCML of caAMR in renal allograft

  • [1] 郭晖. 抗体介导性/体液性排斥反应[M]//陈实, 郭晖. 移植病理学. 北京: 人民卫生出版社, 2009.
    [2] WILLIAMSON CS. Further studies on the transplantation of the kidney[J]. J Urol, 1926, 16(4): 231-254. doi: 10.1016/S0022-5347(17)73405-2
    [3] LEGENDRE CH, KREIS H. A tribute to Jean Hamburger's contribution to organ transplantation[J]. Am J Transplant, 2010, 10(11): 2392-2395. DOI: 10.1111/j.1600-6143.2010.03295.x.
    [4] MITCHISON NA. Passive transfer of transplantation immunity[J]. Proc R Soc Lond B Biol Sci, 1954, 142(906): 72-87. DOI: 10.1098/rspb.1954.0007.
    [5] MASON DW, MORRIS PJ. Effector mechanism in allograft rejection[J]. Ann Rev Immunol, 1986, 4: 119-145. doi: 10.1146/annurev.iy.04.040186.001003
    [6] HALL BM. Cells mediating allograft rejection[J]. Transplantation, 1991, 51(6): 1141-1151. DOI: 10.1097/00007890-199106000-00001.
    [7] TING A. The lymphocytotoxic crossmatch test in clinical renal transplantation[J]. Transplantation, 1983, 35(5): 403-407. DOI: 10.1097/00007890-198305000-00001.
    [8] PHELAN DL, RODEY GE, FLYE MW, et al. Positive B cell crossmatches: specificity of antibody and graft outcome[J]. Transplant Proc, 1989, 21(1 Pt 1): 687-688. http://www.ncbi.nlm.nih.gov/pubmed/2650222
    [9] KARUPPAN SS, LINDHOLM A, MÖLLER E. Characterization and significance of donor-reactive B cell antibodies in current sera of kidney transplant patients[J]. Transplantation, 1990, 49(3): 510-515. DOI: 10.1097/00007890-199003000-00007.
    [10] GORER PA. The detection of antigenic differences in mouse erythrocytes by the employment of immune sera[J]. Br J Exp Pathol, 1936, 17(1): 42-50. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2065193/
    [11] GORER PA. The antigenic basis of tumor transplantation[J]. J Pathol Bacteriol, 1938, 47(2): 231-252. doi: 10.1002/path.1700470204
    [12] GORER PA, O'GORMAN P. The cytotoxic activity of isoantibodies in mice[J]. Transplant Bull, 1956, 3: 142-143. http://ci.nii.ac.jp/naid/10005183924
    [13] KALISS N. Immunological enhancement of tumor homografts in mice: a review[J]. Cancer Res, 1958, 18(9): 992-1003. http://www.ncbi.nlm.nih.gov/pubmed/13596939
    [14] VAN ROOD JJ, EERNISSE JG, VAN LEEUWEN A. Leucocyte antibodies in sera from pregnant women[J]. Nature, 1958, 181(4625): 1735-1736. DOI: 10.1038/1811735a0.
    [15] STARZL TE. Patterns of permissible donor-recipient tissue transfer in relation to ABO blood groups[M]//HUTHEJ. Experience in renal transplantation. Philadelphia: WB Saunders, 1964.
    [16] TERASAKI PI, MCCLELLAND JD. Microdroplet assay of human serum cytotoxins[J]. Nature, 1964, 204: 998-1000. DOI: 10.1038/204998b0.
    [17] KISSMEYER-NIELSEN F, OLSEN S, PETERSEN VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells[J]. Lancet, 1966, 2(7465): 662-665. DOI: 10.1016/s0140-6736(66)92829-7.
    [18] PATEL R, TERASAKI PI. Significance of the positive crossmatch test in kidney transplantation[J]. N Engl J Med, 1969, 280(14): 735-739. DOI: 10.1056/NEJM196904032801401.
    [19] JEANNET M, PINN VW, FLAX MH, et al. Humoral antibodies in renal allotransplantation in man[J]. N Engl J Med, 1970, 282(3): 111-117. DOI: 10.1056/NEJM197001152820301.
    [20] PARK MS, TERASAKI PI, LAU M, et al. Sensitization after transplantation[J]. Clin Transpl, 1987: 393-397.
    [21] HALLORAN PF, WADGYMAR A, RITCHIE S, et al. The significance of the anti-class I antibody response. I. clinical and pathologic features of anti-class I-mediated rejection[J]. Transplantation, 1990, 49(1): 85-91. DOI: 10.1097/00007890-199001000-00019.
    [22] TRPKOV K, CAMPBELL P, PAZDERKA F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, analysis using the Banff grading schema[J]. Transplantation, 1996, 61(11): 1586-1592. DOI: 10.1097/00007890-199606150-00007.
    [23] FEUCHT HE, FELBER E, GOKEL MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection[J]. Clin Exp Immunol, 1991, 86(3): 464-470. DOI: 10.1111/j.1365-2249.1991.tb02954.x.
    [24] FEUCHT HE, SCHNEEBERGER H, HILLEBRAND G, et al. Capillary deposition of C4d complement fragment and early renal graft loss[J]. Kidney Int, 1993, 43(6): 1333-1338. DOI: 10.1038/ki.1993.187.
    [25] COLLINS AB, SCHNEEBERGER EE, PASCUAL MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries[J]. J Am Soc Nephrol, 1999, 10(10): 2208-2214. doi: 10.1681/ASN.V10102208
    [26] BÖHMIG GA, EXNER M, HABICHT A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury[J]. J Am Soc Nephrol, 2002, 13(4): 1091-1099. doi: 10.1681/ASN.V1341091
    [27] SOLEZ K, AXELSEN RA, BENEDIKTSSON H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology[J]. Kidney Int, 1993, 44(2): 411-422. DOI: 10.1038/ki.1993.259.
    [28] HALLORAN PF, SCHLAUT J, SOLEZ K, et al. The significance of the anti-class I response. Ⅱ. clinical and pathologic features of renal transplants with anti-class I-like antibody[J]. Transplantation, 1992, 53(3): 550-555. doi: 10.1097/00007890-199203000-00011
    [29] ROSE SM, STRICKLAND PS, ALDERSON C. Cooperative clinical trial in adult transplantation[J]. NIH Guide, 1995, 24(6): 1-25.
    [30] RACUSEN LC, HALLORAN PF, SOLEZ K. Banff 2003 meeting report: new diagnostic insights and standards[J]. Am J Transplant, 2004, 4(10): 1562-1566. DOI: 10.1111/j.1600-6143.2004.00585.x.
    [31] SOLEZ K, COLVIN RB, RACUSEN LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')[J]. Am J Transplant, 2007, 7(3): 518-526. DOI: 10.1111/j.1600-6143.2006.01688.x.
    [32] SOLEZ K, COLVIN RB, RACUSEN LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions[J]. Am J Transplant, 2008, 8(4): 753-760. DOI: 10.1111/j.1600-6143.2008.02159.x.
    [33] JABS WJ, SEDLMEYER A, RAMASSAR V, et al. Heterogeneity in the evolution and mechanisms of the lesions of kidney allograft rejection in mice[J]. Am J Transplant, 2003, 3(12): 1501-1509. DOI: 10.1046/j.1600-6135.2003.00269.x.
    [34] SIS B, JHANGRI GS, BUNNAG S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining[J]. Am J Transplant, 2009, 9(10): 2312-2323. DOI: 10.1111/j.1600-6143.2009.02761.x.
    [35] GLOOR JM, COSIO FG, REA DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation[J]. Am J Transplant, 2006, 6(8): 1841-1847. DOI: 10.1111/j.1600-6143.2006.01416.x.
    [36] SIS B, REEVE J, EINECKE G, et al. Endothelial stress accelerates graft loss in kidneys with transplant glomerulopathy despite lack of C4d staining[J]. Am J Transplant, 2009, 9(Suppl 2): 349. http://www.researchgate.net/publication/278238899_Endothelial_Stress_Accelerates_Graft_Loss_in_Kidneys_with_Transplant_Glomerulopathy_Despite_Lack_of_C4D_Staining
    [37] WAVAMUNNO MD, O'CONNELL PJ, VITALONE M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies[J]. Am J Transplant, 2007, 7(12): 2757-2768. DOI: 10.1111/j.1600-6143.2007.01995.x.
    [38] MICHAELS PJ, FISHBEIN MC, COLVIN RB. Humoral rejection of human organ transplants[J]. Springer Semin Immunopathol, 2003, 25(2): 119-140. DOI: 10.1007/s00281-003-0139-x.
    [39] MENGEL M, SIS B, HAAS M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection[J]. Am J Transplant, 2012, 12(3): 563-570. DOI: 10.1111/j.1600-6143.2011.03926.x.
    [40] LOUPY A, SUBERBIELLE-BOISSEL C, HILL GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies[J]. Am J Transplant, 2009, 9(11): 2561-2570. DOI: 10.1111/j.1600-6143.2009.02813.x.
    [41] LOUPY A, HILL GS, SUBERBIELLE C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)[J]. Am J Transplant, 2011, 11(1): 56-65. DOI: 10.1111/j.1600-6143.2010.03364.x.
    [42] COSIO FG, LAGER DJ, LORENZ EC, et al. Significance and implications of capillaritis during acute rejection of kidney allografts[J]. Transplantation, 2010, 89(9): 1088-1094. DOI: 10.1097/TP.0b013e3181d368f1.
    [43] COSIO FG, GLOOR JM, SETHI S, et al. Transplant glomerulopathy[J]. Am J Transplant, 2008, 8(3): 492-496. DOI: 10.1111/j.1600-6143.2007.02104.x.
    [44] HAYDE N, BAO Y, PULLMAN J, et al. The clinical and molecular significance of C4d staining patterns in renal allografts[J]. Transplantation, 2013, 95(4): 580-588. DOI: 10.1097/TP.0b013e318277b2e2.
    [45] EINECKE G, SIS B, REEVE J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure[J]. Am J Transplant, 2009, 9(11): 2520-2531. DOI: 10.1111/j.1600-6143.2009.02799.x.
    [46] SIS B, JHANGRI GS, RIOPEL J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants[J]. Am J Transplant, 2012, 12(5): 1168-1179. DOI: 10.1111/j.1600-6143.2011.03931.x.
    [47] GUPTA A, BROIN PÓ, BAO Y, et al. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies[J]. Kidney Int, 2016, 89(1): 217-225. DOI: 10.1038/ki.2015.276.
    [48] HAAS M. Pathology of C4d-negative antibody-mediated rejection in renal allografts[J]. Curr Opin Organ Transplant, 2013, 18(3): 319-326. DOI: 10.1097/MOT.0b013e32835d4daf.
    [49] HAAS M, MIROCHA J. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy[J]. Am J Transplant, 2011, 11(10): 2123-2131. DOI: 10.1111/j.1600-6143.2011.03647.x.
    [50] STEGALL MD, DIWAN T, RAGHAVAIAH S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients[J]. Am J Transplant, 2011, 11(11): 2405-2413. DOI: 10.1111/j.1600-6143.2011.03757.x.
    [51] PAPADIMITRIOU JC, DRACHENBERG CB, RAMOS E, et al. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies[J]. Transplantation, 2013, 95(1): 128-136. DOI: 10.1097/TP.0b013e3182777f28.
    [52] LEFAUCHEUR C, LOUPY A, VERNEREY D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study[J]. Lancet, 2013, 381(9863): 313-319. DOI: 10.1016/S0140-6736(12)61265-3.
    [53] DRAGUN D, MÜLLER DN, BRÄSEN JH, et al. Angiotensin Ⅱ type 1-receptor activating antibodies in renal-allograft rejection[J]. N Engl J Med, 2005, 352(6): 558-569. DOI: 10.1056/NEJMoa035717.
    [54] REINSMOEN NL, LAI CH, MIROCHA J, et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome[J]. Transplantation, 2014, 97(5): 595-601. DOI: 10.1097/01.TP.0000436927.08026.a8.
    [55] ZHANG Q, REED EF. The importance of non-HLA antibodies in transplantation[J]. Nat Rev Nephrol, 2016, 12(8): 484-495. DOI: 10.1038/nrneph.2016.88.
    [56] CHEN G, SEQUEIRA F, TYAN DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads[J]. Hum Immunol, 2011, 72(10): 849-858. DOI: 10.1016/j.humimm.2011.07.001.
    [57] YABU JM, HIGGINS JP, CHEN G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation[J]. Transplantation, 2011, 91(3): 342-347. DOI: 10.1097/TP.0b013e318203fd26.
    [58] LOUPY A, LEFAUCHEUR C, VERNEREY D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival[J]. N Engl J Med, 2013, 369(13): 1215-1226. DOI: 10.1056/NEJMoa1302506.
    [59] SICARD A, DUCREUX S, RABEYRIN M, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss[J]. J Am Soc Nephrol, 2015, 26(2): 457-467. DOI: 10.1681/ASN.2013101144.
    [60] SÜSAL C, WETTSTEIN D, DÖHLER B, et al. Association of kidney graft loss with de novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing[J]. Transplantation, 2015, 99(9): 1976-1980. DOI: 10.1097/TP.0000000000000672.
    [61] FICHTNER A, SÜSAL C, HÖCKER B, et al. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients[J]. Pediatr Nephrol, 2016, 31(7): 1157-1166. DOI: 10.1007/s00467-016-3322-8.
    [62] HIDALGO LG, SIS B, SELLARES J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection[J]. Am J Transplant, 2010, 10(8): 1812-1822. DOI: 10.1111/j.1600-6143.2010.03201.x.
    [63] NICKELEIT V, ZEILER M, GUDAT F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications[J]. J Am Soc Nephrol, 2002, 13(1): 242-251. doi: 10.1681/ASN.V131242
    [64] WIEBE C, GIBSON IW, BLYDT-HANSEN TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody[J]. Am J Transplant, 2015, 15(11): 2921-2930. DOI: 10.1111/ajt.13347.
    [65] LOUPY A, VERNEREY D, TINEL C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts[J]. J Am Soc Nephrol, 2015, 26(7): 1721-1731. DOI: 10.1681/ASN.2014040399.
    [66] LOUPY A, HAAS M, SOLEZ K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology[J]. Am J Transplant, 2017, 17(1): 28-41. DOI: 10.1111/ajt.14107.
    [67] HAAS M, LOUPY A, LEFAUCHEUR C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials[J]. Am J Transplant, 2018, 18(2): 293-307. DOI: 10.1111/ajt.14625.
    [68] LOUPY A, HAAS M, ROUFOSSE C, et al. The Banff 2019 kidney meeting report (Ⅰ): updates on and clarification of criteria for T cell- and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(9): 2318-2331. DOI: 10.1111/ajt.15898.
  • 加载中
图(8)
计量
  • 文章访问数:  344
  • HTML全文浏览量:  69
  • PDF下载量:  43
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-03-22
  • 网络出版日期:  2021-05-19
  • 刊出日期:  2021-05-15

目录

    /

    返回文章
    返回